Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441236 in HIV
NCT03705169Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAR441236 in human immunodeficiency virus type 1 infection (HIV-1) (10 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of Participants Experiencing a Grade 3 or Higher Adverse Event Related to Study Treatment at 36 weeks, Mean Dose-normalized AUC 0-12wk of SAR441236 and 1 more. Started May 2019; status: terminated.
02
Drugs
SAR441236
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03705169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705169.